Gilead Sciences Inc (GILD)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Gilead Sciences Inc (GILD) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013848
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Gilead Sciences Inc (Gilead) is a research-based biopharmaceutical company. It focuses on the discovery, development and commercialization of medicines for the treatment of cardiovascular and respiratory diseases, inflammation, liver diseases, cancer and human immunodeficiency virus (HIV) infection. The company also has a wide range of pipeline products in various therapeutic areas in different stages of development. Gilead sells its products through marketing subsidiaries and distributors and corporate partners in Europe, the Americas, Asia-Pacific, the Middle East and Africa. The major products of the company include Harvoni, Sovaldi, Truvada, Atripla, Stribild, Epclusa, Genvoya, Complera/Eviplera, Viread and others. Gilead is headquartered in Foster City, California, the US.

Gilead Sciences Inc (GILD) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Gilead Sciences Inc, Medical Equipment, Deal Details 11
Partnerships 11
Kite Pharma Enters into Agreement with Vitruvian Networks 11
Debt Offering 12
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40
Acquisition 42
United Therapeutics May Sell Itself 42
Gilead Sciences Inc – Key Competitors 43
Gilead Sciences Inc – Key Employees 44
Gilead Sciences Inc – Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Joint Venture 49
Recent Developments 50
Financial Announcements 50
Oct 26, 2017: Gilead Sciences Announces Third Quarter 2017 Financial Results 50
Jul 26, 2017: Gilead Sciences Announces Second Quarter 2017 Financial Results 52
May 02, 2017: Gilead Sciences Announces First Quarter 2017 Financial Results 54
Feb 07, 2017: Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results 56
Nov 01, 2016: Gilead Sciences Announces Third Quarter 2016 Financial Results 58
Jul 25, 2016: Gilead Sciences Announces Second Quarter 2016 Financial Results 60
Apr 28, 2016: Gilead Sciences Announces First Quarter 2016 Financial Results 62
Feb 02, 2016: Gilead Sciences Announces Fourth Quarter and Full Year 2015 Financial Results 64
Corporate Communications 67
Oct 17, 2017: Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics 67
Sep 27, 2017: Kevin Young CBE, Gilead’s Chief Operating Officer, to Retire 68
Jan 03, 2017: Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head 69
Nov 16, 2016: Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations 70
Aug 23, 2016: Kelly A. Kramer Joins Gilead Sciences’ Board of Directors 71
May 24, 2016: Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy 72
Feb 01, 2016: Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources 73
Jan 29, 2016: Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director 74
Jan 29, 2016: AHF: Gilead Billionaire CEO John Martin Steps Down 75
Government and Public Interest 76
Aug 11, 2016: ATF Urges Treasury and IRS to Act Against Gilead Science’s Massive Offshore Tax Dodging 76
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Gilead Sciences Inc, Medical Equipment, Key Facts, 2016 2
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Gilead Sciences Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Gilead Sciences Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Gilead Sciences Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Gilead Sciences Inc, Deals By Market, 2011 to YTD 2017 9
Gilead Sciences Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Kite Pharma Enters into Agreement with Vitruvian Networks 11
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2018 12
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2019 14
Gilead Sciences Raises USD750 Million in Public Offering of Notes Due 2019 16
Gilead Sciences Raises USD500 Million in Public Offering of Notes Due 2019 18
Gilead Sciences Raises USD1.25 Billion in Public Offering of 2.95% Notes Due 2027 20
Gilead Sciences Raises USD0.5 Billion in Public Offering of 1.95% Notes Due 2022 22
Gilead Sciences Raises USD1.75 Billion in Public Offering of 4.15% Notes Due 2047 24
Gilead Sciences Raises USD0.75 Billion in Public Offering of 4% Notes Due 2036 26
Gilead Sciences Raises USD0.75 Billion in Public Offering of 2.5% Notes Due 2023 28
Gilead Sciences Raises USD2.25 Billion in Public Offering of 4.75% Notes Due 2046 30
Gilead Sciences Raises USD1 Billion in Public Offering of 1.85% Notes Due 2018 32
Gilead Sciences Raises USD1 Billion in Public Offering of 3.25% Notes Due 2022 34
Gilead Sciences Raises USD2 Billion in Public Offering of 2.55% Notes Due 2020 36
Gilead Sciences Raises USD2.75 Billion in Public Offering of 3.65% Notes Due 2026 38
Gilead Sciences Raises USD1 Billion in Public Offering of 4.6% Notes Due 2035 40
United Therapeutics May Sell Itself 42
Gilead Sciences Inc, Key Competitors 43
Gilead Sciences Inc, Key Employees 44
Gilead Sciences Inc, Other Locations 45
Gilead Sciences Inc, Subsidiaries 45
Gilead Sciences Inc, Joint Venture 49

★海外企業調査レポート[Gilead Sciences Inc (GILD)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PT Dahana:企業の戦略・SWOT・財務情報
    PT Dahana - Strategy, SWOT and Corporate Finance Report Summary PT Dahana - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventiona …
  • Bird Rock Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators and therapeutic antiobodies. The company’s pipeline products include RYI-018, Gerilimzumab and Namacizumab. Its RYI-018 is a peripheral antagonist …
  • Recro Pharma Inc (REPH):企業の財務・戦略的SWOT分析
    Recro Pharma Inc (REPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PDL BioPharma Inc:企業の戦略的SWOT分析
    PDL BioPharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Pluspetrol SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Pluspetrol SA (Pluspetrol), a subsidiary of Pluspetrol Resources Corporation N.V. is an oil and gas company that produces oil and gas products. The company’s products include LPG, natural gas, crude oil, liquid fuel, liquid gas and others. It explores and develops oil and gas reserves based …
  • Mitsubishi Heavy Industries, Ltd.:企業の戦略・SWOT・財務分析
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Smith & Nephew plc:企業のM&A・事業提携・投資動向
    Smith & Nephew plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Smith & Nephew plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • DiaGenic ASA (NEL)-医療機器分野:企業M&A・提携分析
    Summary DiaGenic ASA (DiaGenic) is a medical device company that develops innovative in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from th …
  • Illumina Inc (ILMN):企業の財務・戦略的SWOT分析
    Illumina Inc (ILMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • G&K Services LLC:戦略・SWOT・企業財務分析
    G&K Services LLC - Strategy, SWOT and Corporate Finance Report Summary G&K Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Uniqa Montenegro:企業の戦略・SWOT・財務情報
    Uniqa Montenegro - Strategy, SWOT and Corporate Finance Report Summary Uniqa Montenegro - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Subaru Corp (7270):企業の財務・戦略的SWOT分析
    Subaru Corp (7270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Advocate Aurora Health Care:企業の戦略的SWOT分析
    Advocate Aurora Health Care - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • RWE AG:企業の戦略・SWOT・財務情報
    RWE AG - Strategy, SWOT and Corporate Finance Report Summary RWE AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Duke Energy Indiana LLC:企業の発電所・SWOT分析2018
    Duke Energy Indiana LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Societe Generale S.A.:戦略・SWOT・企業財務分析
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • PGE Polska Grupa Energetyczna SA (PGE):企業の財務・戦略的SWOT分析
    PGE Polska Grupa Energetyczna SA (PGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Total System Services Inc (TSS):企業の財務・戦略的SWOT分析
    Total System Services Inc (TSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆